CNS Pharmaceuticals, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. CNS Pharmaceuticals is a clinical-stage oncology company developing treatments for brain and central nervous system cancers. Its lead candidate, Berubicin, is in a randomized study for recurrent glioblastoma; WP1244/WP1874 is an earlier-stage program. The company reported no product sales or revenue from operations.
Financial results and position
| Metric | 2022 | 2021 (revised) |
|---|---|---|
| General and administrative expense | $5.97 million | $4.68 million |
| Research and development expense | $9.30 million | $9.81 million |
| Total operating expenses | $15.27 million | $14.49 million |
| Net loss | $15.27 million | $14.50 million |
| Basic and diluted loss per share | $11.22 | $16.50 |
| Net cash used in operating activities | $10.56 million | $13.54 million |
| Cash and cash equivalents, year-end | $10.06 million | $5.00 million |
At December 31, 2022, working capital was $7.64 million, total assets were $13.05 million, and total liabilities were $4.92 million. Liabilities included $3.68 million of accounts payable, $0.83 million of accrued expenses, and $0.41 million of short-term notes payable. The note financed insurance costs, carried 5.88% interest, and was due by October 2023. No meaningful revenue or profit margins were reported; the company remains loss-making and development-stage.
2022 financing activities provided $15.61 million in net cash, including $16.04 million of net proceeds from common stock issuance. The company completed financings in January and November, with gross proceeds of approximately $11.5 million and $6.0 million, respectively. These transactions, including warrants and pre-funded warrants, increased potential dilution. A 1-for-30 reverse stock split took effect November 28, 2022.
Changes versus 2021
- Net loss increased by approximately $0.78 million. G&A rose by $1.29 million, partly offset by a $0.51 million decrease in R&D. The filing attributes the R&D decrease mainly to lower manufacturing activity and credits related to Berubicin product supplied to WPD, offset by higher clinical-trial CRO costs.
- Operating cash use declined by approximately $2.98 million, while year-end cash increased by approximately $5.05 million, reflecting the 2022 equity financings.
- The company revised 2021 financial statements to record $458,622 of additional R&D expense and accrued costs that its CRO had not reported. It also corrected 2022 interim statements for $367,439 of omitted trial-site costs; management concluded the prior-period errors were not material.
- Outstanding warrants rose substantially during 2022; the filing reports 4.13 million warrants outstanding at year-end, compared with 140,512 at year-end 2021.
Outlook, risks, and notable items
- Funding and going concern: Management estimated year-end cash would fund planned operations into, but not beyond, the third quarter of 2023. The company estimated it would need an additional $8–12 million to complete the Berubicin Phase 2 trial, plus approximately $5 million for near-term WP1244/WP1874 preclinical work and additional operating capital. The auditor cited recurring operating losses and negative operating cash flows that raise substantial doubt about the company’s ability to continue as a going concern. There is no assurance that additional financing will be available on acceptable terms.
- Clinical outlook: The Berubicin trial compares the drug with Lomustine in an estimated 243 patients, randomized 2:1, with overall survival as the primary endpoint. The company anticipated an independent data safety monitoring board’s interim futility analysis and a data release in the third quarter of 2023; this was a forward-looking estimate, not a reported result. Positive data would not guarantee regulatory approval, and further trials or financing may be required.
- Development and commercial risks: Berubicin remains investigational, and evidence cited from an earlier Phase 1 study is limited and does not establish later-stage efficacy. The company has no manufacturing facilities or sales organization and depends on third parties. Its licensed U.S. patents for Berubicin expired in March 2020; orphan-drug designation is described as its primary protection, subject to exceptions. The company also identifies competition, trial enrollment, safety, regulatory, reimbursement, and financing risks.
- Controls and reporting: Management concluded internal control over financial reporting and disclosure controls were ineffective at year-end because of limited segregation of duties, incomplete and delayed CRO cost information, and insufficient control documentation. The CRO reporting weakness was associated with the omitted trial costs and financial-statement corrections. Management described remediation efforts but gave no assurance they would fully resolve the weaknesses.
- Other items: The FDA had granted Berubicin orphan-drug designation and Fast Track designation. The company regained Nasdaq minimum-bid-price compliance in December 2022 after its reverse stock split. Related-party arrangements involving founder-affiliated entities are disclosed. The filing reports no pending legal actions considered material.
Investor facts to verify
- Current cash, subsequent financing, operating cash burn, and the actual runway relative to the company’s stated third-quarter 2023 estimate.
- Whether the Berubicin interim analysis occurred, its findings, trial enrollment and timeline, and any regulatory feedback or additional-study requirements.
- Progress and costs in resolving the CRO-related accrual issue and remediating internal-control weaknesses.
- Current fully diluted share count, warrant exercise terms, and potential dilution from the 2022 financings and later exercises.
- Whether the company secured sufficient funding for Berubicin and WP1244/WP1874 development, and the terms and dilution of any financing.